Outlook Therapeutics Names New CFO Amid LYTENAVA Launch Plans

Outlook Therapeutics has highlighted its newly appointed Chief Financial Officer, Kevin Lundquist, in a Virtual Investor segment. The company is preparing for the U.S. commercial launch of its FDA-approved drug, LYTENAVA, for treating wet age-related macular degeneration (AMD).